NL301276I2 - omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan - Google Patents
omaveloxolon of een farmaceutisch aanvaardbaar zout daarvanInfo
- Publication number
- NL301276I2 NL301276I2 NL301276C NL301276C NL301276I2 NL 301276 I2 NL301276 I2 NL 301276I2 NL 301276 C NL301276 C NL 301276C NL 301276 C NL301276 C NL 301276C NL 301276 I2 NL301276 I2 NL 301276I2
- Authority
- NL
- Netherlands
- Prior art keywords
- omaveloxolone
- pharmaceutically acceptable
- acceptable salt
- salt
- pharmaceutically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261687669P | 2012-04-27 | 2012-04-27 | |
| US201361775288P | 2013-03-08 | 2013-03-08 | |
| US201361780444P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/038064 WO2013163344A1 (en) | 2012-04-27 | 2013-04-24 | 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL301276I2 true NL301276I2 (nl) | 2024-06-24 |
Family
ID=49483867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301276C NL301276I2 (nl) | 2012-04-27 | 2024-05-29 | omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan |
Country Status (40)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104739841B (zh) | 2008-01-11 | 2018-06-01 | 里亚塔医药公司 | 合成三萜类化合物及用以治病之方法 |
| US8124799B2 (en) | 2008-04-18 | 2012-02-28 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
| KR101665042B1 (ko) | 2008-04-18 | 2016-10-11 | 리타 파마슈티컬스 잉크. | 소염성 골격군을 포함하는 화합물 및 사용 방법 |
| JP5857068B2 (ja) | 2010-12-17 | 2016-02-10 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーターとしてのピラゾリルおよびピリミジニル三環式エノン |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| DK2841445T3 (en) | 2012-04-27 | 2017-09-11 | Reata Pharmaceuticals Inc | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONMETHYL, POLYMORPHE FORMS THEREOF AND PROCEDURES FOR USING IT |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| BR112015005168A2 (pt) | 2012-09-10 | 2017-08-15 | Reata Pharmaceuticals Inc | Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos |
| AR096046A1 (es) * | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
| EP3212195A4 (en) | 2014-10-31 | 2018-06-06 | The Regents of The University of California | Compositions and methods for treating hiv-associated cognitive dysfunction |
| NZ734292A (en) | 2015-02-12 | 2022-09-30 | Reata Pharmaceuticals Inc | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| ES2865163T3 (es) | 2015-09-23 | 2021-10-15 | Reata Pharmaceuticals Inc | Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos |
| MA46749A (fr) | 2016-11-08 | 2019-09-18 | Reata Pharmaceuticals Inc | Méthodes de traitement du syndrome d'alport à l'aide d'un méthyle de bardoxolone ou d'analogues de ce dernier |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| KR20210019459A (ko) * | 2018-05-24 | 2021-02-22 | 레니버스 테라퓨틱스, 인크. | 신장 손상 및 신부전 위험이 있는 환자를 치료하는 방법 |
| JP7498122B2 (ja) | 2018-06-15 | 2024-06-11 | リアタ ファーマシューティカルズ インコーポレイテッド | ＩＬ－１７およびＲＯＲγの阻害用のピラゾール化合物およびイミダゾール化合物 |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| WO2020041169A2 (en) | 2018-08-20 | 2020-02-27 | Janssen Pharmaceutica Nv | Inhibitors of keap1-nrf2 protein-protein interaction |
| EA202092684A1 (ru) | 2018-08-27 | 2021-03-11 | Ридженерон Фармасьютикалз, Инк. | Применение рамановской спектроскопии для последующей очистки |
| EP3956342A4 (en) * | 2019-02-15 | 2023-05-24 | Triterpenoid Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR INHIBITION OF NLRP3 INFLAMMASOME AND/OR LON PROTEASE |
| US12344631B2 (en) | 2019-07-19 | 2025-07-01 | Reata Pharmaceuticals, Inc. | C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof |
| CN115023236A (zh) * | 2019-12-03 | 2022-09-06 | 贝勒医学院 | 用于胰岛素抵抗的使用方法的治疗性化合物 |
| EP4093377A1 (en) | 2020-01-24 | 2022-11-30 | Tvardi Therapeutics, Inc. | Therapeutic compounds, formulations, and uses thereof |
| AU2021397631A1 (en) | 2020-12-11 | 2023-07-20 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
| US20240140986A1 (en) | 2021-01-18 | 2024-05-02 | Reata Pharmaceuticals, Inc. | Synthetic ursolic acid derivatives and methods of use thereof |
| CN113197905B (zh) * | 2021-04-23 | 2022-04-19 | 浙江大学 | 三萜类化合物在制备神经母细胞瘤治疗药物中的应用 |
| CN113358627B (zh) * | 2021-06-23 | 2022-07-01 | 华中农业大学 | 一种基于拉曼检测的田间快速测定茶树品质成分的方法 |
| CN114344308A (zh) * | 2021-12-22 | 2022-04-15 | 山西医科大学第二医院 | 甲基巴多索隆在制备防治骨关节炎的药物中的应用 |
| CN117050134A (zh) * | 2022-05-05 | 2023-11-14 | 中国科学院上海有机化学研究所 | 酰胺化合物的合成及其用途 |
| CN119365474A (zh) | 2022-06-15 | 2025-01-24 | 特维迪疗法公司 | Stat3抑制剂的前药 |
| CN115165838B (zh) * | 2022-06-23 | 2025-09-30 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 基于拉曼光谱和血清代谢构建mds和aml鉴别模型的方法和试剂盒 |
| US20240124393A1 (en) | 2022-09-21 | 2024-04-18 | Sicor - Societa Italiana Corticosteroidi S.R.L. | Process and intermediates for preparation of omaveloxolone and salts thereof |
| WO2025029691A1 (en) * | 2023-07-28 | 2025-02-06 | Reata Pharmaceuticals Holdings, LLC | Methods for producing triterpenoid derivatives |
| CN117964678A (zh) * | 2024-01-29 | 2024-05-03 | 烟台大学 | C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5555153Y2 (enExample) | 1975-03-19 | 1980-12-20 | ||
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
| US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| CA2372962C (en) | 1999-05-14 | 2008-04-08 | Nereus Pharmaceuticals, Inc. | Novel interleukin-1 and tumor necrosis factor-.alpha. modulators, syntheses of said modulators and methods of using said modulators |
| US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
| JP2001240573A (ja) | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
| WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| AU2001294959A1 (en) | 2000-09-29 | 2002-04-08 | Robert M. Carlson | Triterpenes having antibacterial activity |
| CA2424013A1 (en) | 2000-09-29 | 2002-04-04 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
| US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
| US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| EP1395255A4 (en) | 2000-11-28 | 2007-09-12 | Univ Texas | CDDO COMPOUNDS AND ASSOCIATED POLYTHERAPIES |
| WO2002092768A2 (en) | 2001-05-14 | 2002-11-21 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
| EP1465615B1 (en) | 2002-01-15 | 2012-08-01 | Trustees of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| EP1465914B1 (en) | 2002-01-18 | 2008-12-17 | Regents Of The University Of Minnesota | Triterpene quaternary salts as biologically active surfactants |
| CA2485565A1 (en) | 2002-05-13 | 2004-08-05 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
| US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
| AU2005282437B2 (en) | 2004-09-07 | 2013-01-10 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
| US20050208151A1 (en) | 2003-10-30 | 2005-09-22 | Entelos, Inc. | Treatment of rheumatoid arthritis with FLIP antagonists |
| WO2005046732A2 (en) | 2003-11-04 | 2005-05-26 | THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH | Methods and compositions for the inhibition of hiv-1 replication |
| US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
| JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
| EP1959969A2 (en) | 2005-07-01 | 2008-08-27 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| WO2007112043A2 (en) | 2006-03-23 | 2007-10-04 | Advanced Life Sciences Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
| WO2007127791A2 (en) | 2006-04-25 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | New pharmacological method for treatment of neuropathic pain |
| JP5610766B2 (ja) | 2006-06-27 | 2014-10-22 | ウェリントン ラボラトリーズ インコーポレイティッド | グリチルレチン酸誘導体 |
| WO2008016095A1 (en) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| WO2008064133A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| LT2653873T (lt) | 2007-02-08 | 2022-10-10 | Biogen Ma Inc. | Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti |
| JP2008247898A (ja) | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| US20080254055A1 (en) | 2007-04-11 | 2008-10-16 | John Erich Oblong | Compositions for Regulation of Hair Growth |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| WO2009023845A2 (en) | 2007-08-15 | 2009-02-19 | The Board Of Regents Of The University Of Texas System | Combination therapy with synthetic triterpenoids and gemcitabine |
| WO2009058849A1 (en) | 2007-10-29 | 2009-05-07 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
| CN104739841B (zh) | 2008-01-11 | 2018-06-01 | 里亚塔医药公司 | 合成三萜类化合物及用以治病之方法 |
| US8124799B2 (en) | 2008-04-18 | 2012-02-28 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
| BRPI0911422B8 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos |
| US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| KR101665042B1 (ko) | 2008-04-18 | 2016-10-11 | 리타 파마슈티컬스 잉크. | 소염성 골격군을 포함하는 화합물 및 사용 방법 |
| EP2279197B1 (en) | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| WO2010011782A1 (en) | 2008-07-22 | 2010-01-28 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| US8778990B2 (en) | 2008-11-04 | 2014-07-15 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| CA2744388A1 (en) | 2008-11-21 | 2010-05-27 | The Johns Hopkins University | Compositions and methods for treating or preventing radiation injury |
| KR101483203B1 (ko) | 2009-02-13 | 2015-01-15 | 리아타 파마슈티컬즈, 아이엔씨. | 무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물 |
| EP3028707A1 (en) | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| AU2011240690C1 (en) | 2010-04-12 | 2014-11-06 | Reata Pharmaceuticals Holdings, LLC | Method of treating obesity using antioxidant inflammation modulators |
| WO2011140078A1 (en) | 2010-05-04 | 2011-11-10 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
| US20130288985A1 (en) | 2010-07-15 | 2013-10-31 | The Schepens Eye Research Institute Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| CN102070697A (zh) | 2010-12-09 | 2011-05-25 | 中国药科大学 | 一种齐墩果酸衍生物、其制备方法及用途 |
| CN102079772A (zh) | 2010-12-09 | 2011-06-01 | 中国药科大学 | 一类五环三萜-13,28-内酯化合物、其制备方法和用途 |
| JP5857068B2 (ja) | 2010-12-17 | 2016-02-10 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーターとしてのピラゾリルおよびピリミジニル三環式エノン |
| SG192144A1 (en) | 2011-01-31 | 2013-08-30 | Bristol Myers Squibb Co | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
| CN102153613B (zh) | 2011-02-28 | 2013-08-14 | 贵州省中国科学院天然产物化学重点实验室 | 夏枯草酸的制备方法和应用 |
| CN102093462B (zh) | 2011-02-28 | 2012-11-21 | 贵州省中国科学院天然产物化学重点实验室 | 1α,2α-二羟基齐墩果酸的制备方法和应用 |
| TR201909788T4 (tr) | 2011-03-11 | 2019-07-22 | Reata Pharmaceuticals Inc | C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri. |
| WO2012154554A1 (en) | 2011-05-06 | 2012-11-15 | Catabasis Pharmaceuticals, Inc. | Fatty acid triterpene derivatives and their uses |
| CN102250189B (zh) | 2011-05-20 | 2012-08-29 | 中国药科大学 | 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途 |
| DK2841445T3 (en) | 2012-04-27 | 2017-09-11 | Reata Pharmaceuticals Inc | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONMETHYL, POLYMORPHE FORMS THEREOF AND PROCEDURES FOR USING IT |
| US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| WO2013169740A2 (en) | 2012-05-08 | 2013-11-14 | Trustees Of Dartmouth College | Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| RU2487884C1 (ru) | 2012-07-13 | 2013-07-20 | Общество с ограниченной ответственностью "Дакор" (ООО "Дакор") | Средство, обладающее антиоксидантной, противовоспалительной, нейропротекторной, гиполипидемической, гипохолестеринемической, гипогликемической, гепатопротекторной, иммуносупрессорной активностями |
| CN103665087A (zh) | 2012-09-03 | 2014-03-26 | 上海源力生物技术有限公司 | 一种萜类化合物及其在医药上的应用 |
| WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| MX2015003021A (es) | 2012-09-10 | 2015-11-09 | Abbvie Inc | Derivados de acido glicirretinico y metodos de uso de los mismos. |
| BR112015005168A2 (pt) | 2012-09-10 | 2017-08-15 | Reata Pharmaceuticals Inc | Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| DK2892911T3 (en) | 2012-09-10 | 2017-10-23 | Reata Pharmaceuticals Inc | C17 heteroaryl derivatives of oleanolic acid and methods of use thereof |
| EP2739639A4 (en) | 2012-09-28 | 2014-11-05 | Applied Pharmaceutical Science Inc | POLYMORPHES OF CDDO ETHYL SITES AND USES THEREOF |
| CN102887936A (zh) | 2012-10-24 | 2013-01-23 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型 |
| CN102875634B (zh) | 2012-10-24 | 2014-08-20 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型 |
| AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
| TWI716341B (zh) | 2013-08-23 | 2021-01-21 | 美商瑞塔醫藥有限責任公司 | 使用齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）或其類似物治療和預防內皮功能障礙之方法 |
| CA2936550C (en) | 2014-01-24 | 2022-07-26 | Abbvie Inc. | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| NZ734292A (en) | 2015-02-12 | 2022-09-30 | Reata Pharmaceuticals Inc | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| ES2865163T3 (es) | 2015-09-23 | 2021-10-15 | Reata Pharmaceuticals Inc | Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos |
| MA46749A (fr) | 2016-11-08 | 2019-09-18 | Reata Pharmaceuticals Inc | Méthodes de traitement du syndrome d'alport à l'aide d'un méthyle de bardoxolone ou d'analogues de ce dernier |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
-
2013
- 2013-04-24 DK DK13720708.0T patent/DK2841445T3/en active
- 2013-04-24 SI SI201330749T patent/SI2841445T1/sl unknown
- 2013-04-24 TW TW102114730A patent/TW201348245A/zh unknown
- 2013-04-24 US US13/869,833 patent/US8993640B2/en active Active
- 2013-04-24 UY UY0001034764A patent/UY34764A/es active IP Right Grant
- 2013-04-24 WO PCT/US2013/038064 patent/WO2013163344A1/en not_active Ceased
- 2013-04-24 LT LTEP13720708.0T patent/LT2841445T/lt unknown
- 2013-04-24 KR KR1020147032968A patent/KR102101774B1/ko active Active
- 2013-04-24 HU HUE17175885A patent/HUE053113T2/hu unknown
- 2013-04-24 HU HUE13720708A patent/HUE035673T2/en unknown
- 2013-04-24 ES ES17175885T patent/ES2861393T3/es active Active
- 2013-04-24 EP EP17175885.7A patent/EP3444261B1/en active Active
- 2013-04-24 SM SM20170396T patent/SMT201700396T1/it unknown
- 2013-04-24 PT PT137207080T patent/PT2841445T/pt unknown
- 2013-04-24 ES ES13720708.0T patent/ES2634315T3/es active Active
- 2013-04-24 RS RS20210286A patent/RS61544B1/sr unknown
- 2013-04-24 RS RS20170770A patent/RS56154B1/sr unknown
- 2013-04-24 EP EP13720708.0A patent/EP2841445B1/en active Active
- 2013-04-24 JP JP2015509119A patent/JP6410710B2/ja active Active
- 2013-04-24 BR BR112014026640-9A patent/BR112014026640B1/pt active IP Right Grant
- 2013-04-24 AR ARP130101383A patent/AR092823A1/es not_active Application Discontinuation
- 2013-04-24 UA UAA201412683A patent/UA116209C2/uk unknown
- 2013-04-24 PL PL17175885T patent/PL3444261T3/pl unknown
- 2013-04-24 LT LTEP17175885.7T patent/LT3444261T/lt unknown
- 2013-04-24 TW TW106112410A patent/TWI623548B/zh active
- 2013-04-24 HK HK15107525.2A patent/HK1207085A1/xx unknown
- 2013-04-24 DK DK17175885.7T patent/DK3444261T3/da active
- 2013-04-24 NZ NZ630222A patent/NZ630222A/en unknown
- 2013-04-24 CN CN201380034275.0A patent/CN104395332B/zh active Active
- 2013-04-24 EA EA201491972A patent/EA030468B1/ru unknown
- 2013-04-24 CA CA2869783A patent/CA2869783C/en active Active
- 2013-04-24 AU AU2013251602A patent/AU2013251602B2/en active Active
- 2013-04-24 MX MX2014013076A patent/MX357060B/es active IP Right Grant
- 2013-04-24 SG SG11201406868XA patent/SG11201406868XA/en unknown
- 2013-04-24 HR HRP20171275TT patent/HRP20171275T1/hr unknown
- 2013-04-24 MX MX2018007876A patent/MX387999B/es unknown
- 2013-04-24 SM SM20210166T patent/SMT202100166T1/it unknown
- 2013-04-24 SI SI201331856T patent/SI3444261T1/sl unknown
- 2013-04-24 MY MYPI2014003024A patent/MY172750A/en unknown
- 2013-04-24 PT PT171758857T patent/PT3444261T/pt unknown
- 2013-04-24 ME MEP-2017-178A patent/ME02926B/me unknown
- 2013-04-24 PE PE2014001894A patent/PE20150160A1/es active IP Right Grant
- 2013-04-24 PL PL13720708T patent/PL2841445T3/pl unknown
-
2014
- 2014-10-09 ZA ZA2014/07326A patent/ZA201407326B/en unknown
- 2014-10-21 DO DO2014000236A patent/DOP2014000236A/es unknown
- 2014-10-22 IL IL235275A patent/IL235275B/en active IP Right Grant
- 2014-10-24 CL CL2014002886A patent/CL2014002886A1/es unknown
- 2014-10-29 CO CO14240045A patent/CO7170182A2/es unknown
-
2015
- 2015-02-19 US US14/625,829 patent/US9701709B2/en active Active
-
2017
- 2017-06-14 US US15/622,568 patent/US11078230B2/en active Active
- 2017-09-12 CY CY20171100959T patent/CY1119333T1/el unknown
-
2018
- 2018-09-25 JP JP2018178470A patent/JP6637136B2/ja active Active
-
2021
- 2021-03-26 CY CY20211100266T patent/CY1124130T1/el unknown
- 2021-06-25 US US17/304,778 patent/US12065464B2/en active Active
-
2024
- 2024-04-17 LT LTPA2024511C patent/LTC2841445I2/lt unknown
- 2024-04-17 FR FR24C1015C patent/FR24C1015I2/fr active Active
- 2024-04-18 FI FIC20240012C patent/FIC20240012I1/fi unknown
- 2024-04-18 HU HUS2400010C patent/HUS2400010I1/hu unknown
- 2024-04-25 CY CY2024012C patent/CY2024012I1/el unknown
- 2024-05-29 NL NL301276C patent/NL301276I2/nl unknown
- 2024-07-09 US US18/767,855 patent/US20250051388A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301276I2 (nl) | omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301131I2 (nl) | pemigatinib of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301292I2 (nl) | Iptacopan of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301119I2 (nl) | Selinexor of een farmaceutisch aanvaardbaar zout ervan | |
| NL301253I2 (nl) | mavacamten of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301254I2 (nl) | Futibatinib of een zout daarvan | |
| NL301248I2 (nl) | atogepant of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301201I2 (nl) | Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride | |
| NL301157I2 (nl) | odevixibat of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301191I2 (nl) | voxelotor of een tautomeer of farmaceutisch aanvaardbaar zout daarvan | |
| NO2021041I1 (no) | remimazolam or a pharmaceutically acceptable salt thereof | |
| NL301318I2 (nl) | Erdafitinib of een farmaceutisch aanvaardbaar zout daarvan of een solvaat daarvan | |
| NL301294I2 (nl) | Dasiglucagon of een farmaceutisch aanvaardbaar zout of solvaat daarvan, zoals dasiglucagon hydrochloride | |
| FIC20230028I1 (fi) | Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola | |
| NO2022010I1 (no) | ripretinib, or a pharmaceutically acceptable salt thereof | |
| NL301341I2 (nl) | eplontersen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301234I2 (nl) | maralixibat of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder maralixibatchloride | |
| NL301197I2 (nl) | daridorexant of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder daridorexanthydrochloride | |
| NL301245I2 (nl) | Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NO2022005I1 (no) | Zanubrutinib or a pharmaceutically acceptable salt thereof | |
| NL301084I2 (nl) | remdesivir of een farmaceutisch aanvaardbaar zout of ester daarvan | |
| NL301155I2 (nl) | abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301128I2 (nl) | Risdiplam of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301006I2 (nl) | Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL300901I2 (nl) | pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan |